Bacterial Antigen Ingredients TRIZ Cases

Tissue-selective promoters restrict replication-competent controlled alpha-herpesvirus vectors to inoculation sites, preventing neural reactivation.

Freeze-dried recombinant bacteria deliver oral vaccines, eliminating injection complexity while controlling Lyme disease transmission.

LPS-derived immune modulators prime poultry immune pathways to reduce coccidiosis severity and antibiotic reliance.

Using phase-dependent antigens to stimulate host cells for detecting cytokine profiles that distinguish active tuberculosis from latent infection.

Recombinant Mycoplasma antigens replace live attenuated strains to resolve low potency and adverse effects, inducing durable immunity against CBPP.

A measurement method uses bromocresol green dye binding to human serum albumin for quantification.

Increasing carbohydrate antigen density to a 5:1 ratio with an OBI-821 saponin adjuvant overcomes low immunogenicity and insufficient IgG production.

MHC multimers extend complex half-life and binding affinity to resolve weak monomer stability in tuberculosis diagnostics.

High-affinity monoclonal antibodies dissolve persistent biofilms by extracting DNABII proteins, overcoming antibiotic resistance without increasing toxicity.

Engineered microbes detect virulent and spore pathogen states to release targeted therapeutic agents.

Recombinant BCG vaccine shifts immune response to Th1 type, reducing viral load and inflammatory hyper-responsiveness.

CMV vectors deliver Mycobacterium tuberculosis fusion proteins to elicit strong CD4+ and CD8+ T cell responses, overcoming inadequate vaccine reliability.

Combining multiple cytokines into a single signature panel improves diagnostic sensitivity while distinguishing active from past Lyme disease infections.

Disrupting phosphatidylthreonine synthase in coccidian parasites eliminates pathogenic virulence while retaining immunogenicity for effective vaccination.

Salmonella Ecotin polypeptides protect antigens from gastrointestinal degradation and prevent immune tolerance, enabling effective oral vaccination.

Oil-in-water emulsion nanoadjuvants eliminate protein allergens while boosting therapeutic antibody fractions against Clostridium difficile.

Monoclonal antibodies differentiate emerging pneumococcal serotypes like 6C, resolving vaccine coverage gaps caused by non-vaccine strain replacement.

Reducing non-HPV 16/18 VLP doses lowers total antigen amount while maintaining protective response against multiple cancer-causing types.

CD1d binding motifs modify peptides to activate NKT cells, bypassing MHC escape mechanisms that limit intracellular pathogen recognition.

Outer membrane vesicles from Francisella and Piscirickettsia induce B- and T-cell responses without safety risks of live attenuated vaccines.

Synthetic mRNA encoding bacterial proteins induces rapid antigen expression in tumor cells without entering the nucleus.

Phytonutrient feed additives stimulate vaccine-induced immunity against apicomplexa parasites in non-human monogastric animals and ruminants.

ADXS31-164 recombinant Listeria vaccine targets dominant and sub-dominant HER2/neu epitopes, preventing tumor escape mutations while breaking immune tolerance.

IgM protease antigen vaccine elicits protective immunity in piglets before weaning, bypassing maternal antibody interference.

Streptococcus thermophilus TCI633 relieves osteoarthritis symptoms without the gastrointestinal side effects of conventional anti-inflammatory drugs.

Cholesterol-dependent cytolysin proteins in minicells generate diverse anticancer immunity while eliminating toxicity from live bacteria.

CbpA-based fusion proteins overcome limited serotype coverage in existing vaccines by targeting conserved bacterial structures.

Recombinant microbial transglutaminase forms immunologically reactive complexes with gliadin peptides to detect specific antibodies.

Incorporating TLR agonists and oil-in-water emulsions into TdaP booster vaccines to enhance immunogenicity with reduced antigen doses.

Microneedle arrays embed liquid vaccines in solid matrices to enable self-administration while maintaining stability and reducing pain.

Concentrated CctA protein in the vaccine formulation reduces required bacterial dose while maintaining protection against blackleg.

Spray-dried liposomal nanocomposite microparticles stabilize pneumococcal antigens, reducing production costs while ensuring broad serotype coverage.

An mRNA vaccine encodes Borrelia antigens within a lipid nanoparticle delivery system.

Commensal bacteria induce cross-reactive neutralizing antibodies against the SARS-CoV spike protein, bypassing traditional vaccine side effects.

HA protein complex adjuvant accelerates IgG and secretory IgA antibody production while avoiding inflammation from bacterial toxins.

Controlled N-acetylgalactosamine ratios in serotype 12F glycoconjugates resolve production safety limits while boosting immune response.

Fucoidan-quaternized chitosan nanoparticles deliver antigens via polyelectrolyte complexation to enhance immune responses.

Virulent strain cell wall fragments replace isoniazid to reduce viable bacilli in lungs and spleen while avoiding prolonged treatment side effects.

Aldehyde cross-linked chitosan adjuvants eliminate injection-site reactions while generating robust mucosal immunity.

Specific gene knockouts in Brucella canis resolve the contradiction between vaccine coverage and genetic stability.

Nano-satellite complexes deliver type I interferon agonists to activate antigen-presenting cells in hypo-immunogenic tumors.

Enzymatic biotinylation with monovalent streptavidin controls antigen stoichiometry on virus-like particles, resolving self-assembly disruption.

Targeted amino acid substitutions in the binding pocket enable non-neuronal SNARE protein cleavage, resolving limited substrate specificity.

A polysaccharide linker forms amide bonds with carrier proteins to create stable glycoconjugates.

Fusing tetanus toxin fragment C to bacterial antigens within recombinant poxvirus vectors enhances antibody response magnitude.

Specific excipients like melibiose increase protein melting temperatures, enabling stable storage at 60°C without cold chain infrastructure.

Co-administering an immune stimulator with an IL-25 inhibitor overcomes insufficient mucosal immunity by boosting T cell avidity.

Segmenting diverse Streptococcus pneumoniae serotypes into unified polysaccharide-protein conjugates resolves limited vaccine coverage against emerging strains.